Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity
Toxicologic Pathology · 2023-10 · 51 (7-8) · 405-413
DOI: 10.1177/01926233231212255 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 20.11.2023. Verfasst von Chitra Saran und 1 weiteren Autor:innen. Beteiligte Einrichtung: Transporter Sciences, Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics (PDMB), Merck & Co., Inc., West Point, Pennsylvania, USA. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions, Carrier Proteins, Membrane Glycoproteins. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Drug-induced liver injury (DILI) remains a major concern in drug development from a patient safety perspective because it is the leading cause of acute liver failure. One mechanism of DILI is altered bile acid homeostasis and involves several hepatic bile acid transporters. Functional impairment of some hepatic bile acid transporters by drugs, disease, or genetic mutations may lead to toxic accumulation of bile acids within hepatocytes and increase DILI susceptibility. This review focuses on the role of hepatic bile acid transporters in DILI. Model systems, primarily in vitro and modeling tools, such as DILIsym, used in assessing transporter-mediated DILI are discussed. Due to species differences in bile acid homeostasis and drug-transporter interactions, key aspects and challenges associated with the use of preclinical animal models for DILI assessment are emphasized. Learnings are highlighted from three case studies of hepatotoxic drugs: troglitazone, tolvaptan, and tyrosine kinase inhibitors (dasatinib, pazopanib, and sorafenib). The development of advanced in vitro models and novel biomarkers that can reliably predict DILI is critical and remains an important focus of ongoing investigations to minimize patient risk for liver-related adverse reactions associated with medication use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transporter Sciences, Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics (PDMB), Merck & Co., Inc., West Point, Pennsylvania, USA.
- UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Chitra Saran
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Saran, C., & Brouwer, K. L. R. (2023). Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity. Toxicologic Pathology, 51(7-8), 405-413. https://doi.org/10.1177/01926233231212255
Vancouver
Saran C, Brouwer KLR. Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity. Toxicologic Pathology. 2023;51(7-8):405-413. doi:10.1177/01926233231212255
BibTeX
@article{Saran2023,
author = {Saran, Chitra and Brouwer, Kim L R},
title = {Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity},
journal = {Toxicologic Pathology},
year = {2023},
volume = {51},
number = {7-8},
pages = {405--413},
doi = {10.1177/01926233231212255}
}
EUVIMED